Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Oracle Corporation (ORCL) Drops On Miss: Is It A Good Buy Now?

Page 1 of 2

Is Oracle Corporation (NYSE:ORCL) a good stock to buy now? The software giant dropped today after disappointing fiscal 2015 fourth quarter results which saw the company’s profit fall 24.36% to $2.76 billion, or $0.62 per share, down from $3.65 billion, or $0.80 per share, in the same quarter a year ago. Adjusted earnings for the quarter which ended May 31 was $3.5 billion, or $0.78 per share on revenue of $10.71 billion. According to data from Thomson Reuters, analysts expected the company to report $0.86 earnings per share on $10.92 billion in revenue. Furthermore, several brokerage firms have reduced their price target on Oracle. As an example Wedbush Securities has reaffirmed its Neutral rating on the stock while reducing its price target to $40 per share.

Oracle, which is one of the biggest software companies in the World, is blaming foreign exchange headwinds for its lackluster quarter. The firm said that its performance for the recent quarter was “significantly impacted by the strengthening of the U.S. dollar compared to foreign currencies.” If it were not for the U.S. dollar, the technology veteran’s revenues for its fourth quarter would have jumped 3%, the company said.

Oracle ORCL

Ken Wolter/


Nonetheless, investors should be aware of a decrease in enthusiasm about the technology firm from smart money lately. Oracle was in 59 hedge funds’ portfolio at the end of March. There were 62 hedge funds in our database with ORCL holdings at the end of the previous quarter.

First a quick word on why we track hedge fund activity. In 2014, equity hedge funds returned just 1.4%. In 2013, that figure was 11.3%, and in 2012, they returned just 4.8%. These are embarrassingly low figures compared to the S&P 500 ETF (SPY)’s 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. Does this mean that hedge fund managers are dumber than a bucket of rocks when it comes to picking stocks? The answer is definitely no. Our small-cap hedge fund strategy, which identifies the best small-cap stock picks of the best hedge fund managers returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012, outperforming the market each year (it’s outperforming the market so far in 2015 too). What’s the reason for this discrepancy you may ask? The reason is simple: size. Hedge funds have gotten so large, they have to allocate the majority of their money into large-cap liquid stocks that are more efficiently priced. They are like mutual funds now. Consider Ray Dalio’s Bridgewater Associates, the largest in the industry with about $165 billion in AUM. It can’t allocate too much money into a small-cap stock as merely obtaining 2% exposure would really move the price. In fact, Dalio can’t even obtain 2% exposure to many small-cap stocks, even if he essentially owned the entire company, as they’re simply too small (or rather, his fund is too big). This is where we come in. Our research has shown that it is actually hedge funds’ small-cap picks that are their best performing ones and we have consistently identified the best picks of the best managers, returning 144% since the launch of our small-cap strategy compared to less than 60% for the S&P 500 (see the details).

With that in mind, we can also see some slightly negative sentiment from insiders of the company. For example, Co-Chief Executive Officer Safra Catz unloaded 3.75 million shares of the company by the end of March. Co-CEO Mark Hurd also sold 375,000 shares of the company by the start of April.

Considering all of these, we’re going to analyze the key hedge fund action surrounding Oracle Corporation (NASDAQ:ORCL).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!